anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine composition for treating alopecia areata. The composition consists of orally taken medicines and external medicines. The orally taken medicines consist of ruddle and unprepared fleece-flower root with the weight ratio of 1:1, wherein the ruddle and the unprepared fleece-flower root are fine powder; and the external medicines consist of 50 to 200ml of ethyl alcohol with the concentration of 75%, 30 to 50g of cacumen biotae, and 100 g of sliced fresh ginger. The alopecia areata is generally caused by subcutaneous blood stasis, and for most of the alopecia areata, patients do not feel painful. For the traditional Chinese medicine composition disclosed by the invention, the orally taken medicines and the external medicines are combined to enable the alopecia areata to be cured and eradicated thoroughly, and the possibility of relapse is low. The ruddle in the composition can be used for promoting blood circulation and removing blood stasis, the unprepared fleece-flower root can be used for nourishing blood and generating hairs, the ethyl alcohol can be used for promoting blood circulation, the cacumen biotae can be used for removing heat and cooling blood, the fresh ginger can be used for promoting blood circulation and removing blood stasis, and the components are common, so that the cost is relatively low.
Participants will be enrolled in study at initial clinic visit by study staff at which time diagnosis of R-CECS will be established based on elevated pressure measurements in patients who have had surgical release of the affected compartments. Pressure testing will be performed outside of the clinical study and will be required to establish the diagnosis of R-CECS.

Initial clinic visit with study staff will consist of baseline measurements of ankle plantarflexion, dorsiflexion, inversion, and eversion strength using Kiio Force Sensor. The clinic visit with study staff will establish time point 0 and will consist of written consent for participation, Botox injection, and baseline University of Wisconsin Running Index (UWRI). Two months following this visit, the participant will have follow up with study staff. Study staff will again measure ankle strength (ankle inversion, eversion, plantarflexion, and dorsiflexion) using the Kiio Force Sensor utilizing the same strength assessment protocol. Study staff will monitor for side effects and administer the UWRI. Telephone follow up assessment of the UWRI will be made by study staff at 4 and 6 months.
Two electrodes are positioned at M1 and supra-orbital área. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes. The procedure will be repeated at five consecutive days.
Subjects with a weight between 20 kg to \< 50 kg will receive apremilast 20 mg BID and subjects with weight ≥ 50 kg at Visit 1 will receive apremilast 30 mg BID. Subjects that begin the study receiving apremilast 20 mg BID and later record a body weight ≥ 50 kg, will be switched to apremilast 30 mg BID.
FIELD: medicine, endocrinology, gynecology. SUBSTANCE: state of pituitary-aderenal system is estimated by determination of cortizol, somatotropin and aldosterone concentrations. Normal state of pituitary-adrenal system is estimated at combination of high level of cortizol concentration (667.5 ± 10.05 nM) with increased somatotropin concentration (5.67 ± 1.10 ng/ml) and aldosterone content (142.61 ± 10.64 pg/ml) and also at combination of low or median cortizol level with low or median somatotropin and aldosterone content. Other concentrations of cortizol, somatotropin and aldosterone indicate the deviation of pituitary-adrenal system state from norm. Method can be used in therapy, surgery also for detection of persons with risk factors. EFFECT: improved method of estimation. 2 tbl
Sialorrhea is excessive flow of saliva associated with its unintentional loss from the mouth, commonly known as drooling. Sialorrhea may result from any combination of hypersecretion, problems swallowing or sensorimotor problems containing saliva in the mouth. It is commonly found in people with neurological dysfunction such as Parkinson's Disease, leading to social isolation and embarrassment. In general, treatment options are limited because of the underlying chronic disease. The objective of the proposed low-dose, new combination drug, OC Oral solution is to develop a new treatment option that can be used to titrate saliva secretion rates to a level that is low enough to prevent unintentional loss (i.e. drooling) but not so low as to cause an uncomfortably dry mouth.
Sunitinib can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in < 0.1% of patients.

Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with sunitinib. 

Monitor QT interval more frequently when sunitinib is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing sunitinib [see Dosage and Administration (2.5), Drug Interactions (7.2)].
Treatment of HIV-1 Infection

No pediatric clinical trial was conducted to evaluate the safety and efficacy of Emtricitabine and Tenofovir disoproxil fumarate tablets in patients with HIV-1 infection. Data from previously conducted trials with the individual drug products, FTC and TDF, were relied upon to support dosage recommendations for Emtricitabine and Tenofovir disoproxil fumarate tablets. For additional information, consult the prescribing information for EMTRIVA and VIREAD.

Emtricitabine and Tenofovir disoproxil fumarate tablets should only be administered to HIV-1 infected pediatric patients with body weight greater than or equal to 17 kg and who are able to swallow a tablet. Because it is a fixed-dose combination tablet, Emtricitabine and Tenofovir disoproxil fumarate tablets cannot be adjusted for patients of lower weight [see Warnings and Precautions (5.5), Adverse Reactions (6.1) and Clinical Pharmacology (12.3)]. Emtricitabine and Tenofovir disoproxil fumarate tablets is not approved for use in pediatric patients weighing less than 17 kg. 

HIV-1 PrEP

The safety and effectiveness of Emtricitabine and Tenofovir disoproxil fumarate tablets for HIV-1 PrEP in at-risk adolescents weighing at least 35 kg is supported by data from adequate and well-controlled studies of Emtricitabine and Tenofovir disoproxil fumarate tablets for HIV-1 PrEP in adults with additional data from safety and pharmacokinetic studies in previously conducted trials with the individual drug products, FTC and TDF, in HIV-1 infected adults and pediatric subjects [see Dosage and Administration (2.5), Adverse Reactions (6.1), Clinical Pharmacology (12.3 and 12.4), and Clinical Studies (14.3 and 14.4)].

Safety, adherence, and resistance were evaluated in a single-arm, open-label clinical trial (ATN113) in which 67 HIV-1 uninfected at-risk adolescent men who have sex with men received Emtricitabine and Tenofovir disoproxil fumarate tablets once daily for HIV-1 PrEP. The mean age of subjects was 17 years (range 15 to 18 years); 46% were Hispanic, 52% Black, and 37% White. The safety profile of Emtricitabine and Tenofovir disoproxil fumarate tablets in ATN113 was similar to that observed in the adult HIV-1 PrEP trials [see Adverse Reactions (6.1)]. 

In the ATN113 trial, HIV-1 seroconversion occurred in 3 subjects. Tenofovir diphosphate levels in dried blood spot assays indicate that these subjects had poor adherence. No tenofovir- or FTC- associated HIV-1 resistance substitutions were detected in virus isolated from the 3 subjects who seroconverted [see Microbiology (12.4)].

Adherence to study drug, as demonstrated by tenofovir diphosphate levels in dried blood spot assays, declined markedly after Week 12 once subjects switched from monthly to quarterly visits, suggesting that adolescents may benefit from more frequent visits and counseling. [see Warnings and Precautions (5.2)]. 

Safety and effectiveness of Emtricitabine and Tenofovir disoproxil fumarate tablets for HIV-1 PrEP in pediatric patients weighing less than 35 kg have not been established.
PROBLEM TO BE SOLVED: To obtain the subject agent effective also against penicillin-resistant strain by formulating a β-lactam-based antibiotic or salt thereof with a β- lactamase inhibitor in specific proportions. SOLUTION: This agent is obtained by formulating (A) a β-lactam-based antibiotic (pref. amoxicillin as a penicillin-based antibiotic) with (B) a β- lactamase inhibitor (pref. clavulanic acid) in a weight ratio of (1:3) to (13:1), pref. (1:1.5) to (7:1). The fish to be administered with this agent includes Sparidae such as red sea bream and Carangidae such as yellowtail and horse mackerel. This agent is pref. orally administered to cultured fishes and, in this case, it is pref. administered at 20-40 mg/kg for 4 to 7 days in terms of an amoxicillin- based antibiotic.
The participants will receive low-intensity general exercise and pelvic floor muscle training in low-intensity group. The intensity of aerobic exercise is 40\~59% of HRR or VO2R, which is equivalent to the moderate intensity exercise proposed in ACSM. The intensity of resistance exercise is 40\~50% of 1RM, which is equivalent to the very light-to-light intensity exercise proposed in ACSM. After finishing the general exercise, participants will receive pelvic floor muscle training.
Provided is a skin temperature elevating agent able to elevate the skin temperature in a more effective manner. Also provided are a cosmetic composition, foods, and miscellaneous goods having a skin temperature elevating effect. The skin temperature elevating agent of the invention comprises at least two ingredients selected from: the extract of Mentha arvensis var. piperascens, the extract of Salvia sclarea, dihydro-β-ionol, and geraniol. In addition, the skin temperature elevating agent is able to elevate the temperature on the skin of the cheeks. Moreover, the skin temperature elevating agent comprises at least two ingredients selected from: the extract of Mentha arvensis var. piperascens, the extract of Juniper berry, and 4-methoxystyrene so that the skin temperature elevating agent is able to elevate the temperature on the skin of the finger tips. Therefore, the skin temperature elevating agent is able to elevate the skin temperature in a more effective manner. Additionally, the cosmetic composition, foods, and miscellaneous goods containing the skin temperature elevating agent also have a skin temperature elevating effect. Preferably, the Mentha arvensis var. piperascens, the extract of Salvia sclarea, dihydro-ss-ionol, or geraniol is 0.001 mass percentages to 50 mass percentages of the skin temperature elevating agent.
Childhood obesity prevalence in the USA continues to rise and the Hispanic American population is disproportionately affected. Obesity prevalence among Hispanic youth is 26.2%, the highest prevalence of any minority or non-minority group of children. Prevalence of related conditions including type 2 diabetes, heart disease, and stroke also are increased among Hispanic Americans. Physicians and other providers commonly utilize body mass index (BMI) to estimate percentage of bodily fat and risk of adverse health outcomes. BMI has been shown to track from childhood to adulthood, demonstrating necessity for early intervention. Interventions targeting the prevention and reversal of obesity among children are categorized as school-based or family-based. Interventions vary but may involve strategies such as meetings to discuss health-related curriculum, augmentation of physical activity, and/or improvement of nutritional quality of food. The aim of this article is to review the current literature to determine whether family-based or school-based interventions are more successful in the prevention and reversal of obesity among Hispanic youth. We reviewed twenty-eight studies describing these interventions and included ten (four school-based and six family-based) in our in-depth analysis. Inclusion criteria required trials were conducted among adequate population sizes of Hispanic youth within the age range of interest, analyzed the primary outcome of interest, and took place after the year 2000. Family-based interventions typically involved small population sizes, were dependent upon parent adherence, and were rarely effective. School-based interventions were more commonly effective and involved larger population sizes, allowing for greater generalizability and greater impact of the intervention. Of five family or school-based interventions which successfully reduced BMI among this population, four included a component involving structured physical activity. School-based interventions involving augmentation of physical activity with minimal limitations of study execution demonstrated efficacy in the prevention and reversal of obesity among Hispanic children.
SAJAZIR (icatibant) injection is supplied as a single-dose, prefilled syringe for subcutaneous administration. Each syringe delivers 3 mL of a sterile solution of icatibant 30 mg (as icatibant acetate). Each glass syringe has a bromobutyl plunger stopper, which is not made of latex natural rubber. 

SAJAZIR is available in cartons containing one single-dose, prefilled syringe and one 25 G Luer lock needle. NDC 70709-013-01. 

SAJAZIR is also available in a pack containing 3 cartons; each carton contains one single-dose, prefilled syringe and one 25 G Luer lock needle. NDC 70709-013-03.
BACKGROUND: Metastatic carcinoma of unknown primary origin to the head and neck lymph nodes (HNCUP) engenders unique diagnostic considerations. In many cases, the detection of a high-risk human papillomavirus (HR-HPV) unearths an occult oropharyngeal squamous cell carcinoma (SCC). In metastatic HR-HPV-independent carcinomas, other primary sites should be considered, including cutaneous malignancies that can mimic HR-HPV-associated SCC. In this context, ultraviolet (UV) signature mutations, defined as ≥ 60% C→T substitutions with ≥ 5% CC→TT substitutions at dipyrimidine sites, identified in tumors arising on sun exposed areas, are an attractive and underused tool in the setting of metastatic HNCUP.
METHODS: A retrospective review of institutional records focused on cases of HR-HPV negative HNCUP was conducted. All cases were subjected to next generation sequencing analysis to assess UV signature mutations.
RESULTS: We identified 14 HR-HPV negative metastatic HNCUP to either the cervical or parotid gland lymph nodes, of which, 11 (11/14, 79%) had UV signature mutations, including 4 (4/10, 40%) p16 positive cases. All UV signature mutation positive cases had at least one significant TP53 mutation and greater than 20 unique gene mutations.
CONCLUSION: The management of metastatic cutaneous carcinomas significantly differs from other HNCUP especially metastatic HR-HPV-associated SCC; therefore, the observation of a high percentage of C→T with CC →TT substitutions should be routinely incorporated in next generation sequencing reports of HNCUP. UV mutational signatures testing is a robust diagnostic tool that can be utilized in daily clinical practice.
BACKGROUND: Rhus coriaria L., commonly known as Sumac, is a plant from the Anacardiaceae family that is known for its high phytochemical content. These phytochemicals have the potential to effectively manage inflammation and oxidative stress. To explore the existing evidence on the impact of Sumac consumption on inflammation and oxidative stress, we conducted a systematic review of randomized controlled trials.
METHODS: We conducted a comprehensive search of Medline/PubMed, Scopus, and Web of Science from inception to August 2023 to identify relevant studies examining the effects of Sumac on biomarkers of inflammation and oxidative stress. The selected studies were assessed for risk of bias using the Cochrane tool.
RESULTS: A total of seven trials were included in this review. Among these trials, three focused on diabetes patients, while the remaining four involved individuals with fatty liver, overweight individuals with depression, and those with polycystic ovary or metabolic syndrome. Five studies reported the effects of Sumac on oxidative stress, with four of them demonstrating a significant reduction in malondialdehyde (MDA) levels and an increase in total antioxidant capacity (TAC) and paraoxonase 1 (PON1). Regarding inflammation, one study reported no significant difference in tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels between the intervention and control groups. The results for high-sensitivity C-reactive protein levels, reported in five trials, were inconsistent.
CONCLUSION: Sumac consumption over time may positively affect oxidative stress, although short-term use shows minimal impact. While one study found no significant effect on IL-6 and TNF-α, hs-CRP levels could decrease or remain unchanged. Further meta-analyses are needed to fully understand Sumac's potential benefits in managing metabolic diseases.
The present invention relates to amino acids, complexes, and compounds comprising deuterium and tritium isotopes preferably alpha deuterated amino acids, polypeptides, antibodies, derivatives and saccharide-amino acid complexes and conjugates. In some embodiments, the invention relates to methods of using compounds comprising deuterium for imaging biochemical concentrations and distributions in mammalian tissues using nuclear magnetic resonance spectroscopy. In some embodiments, the invention relates to the used of said amino acids derivatives and complexes in boron neutron capture therapy. In some embodiments, the present invention relates to the preparation of amino acids, polypeptides, antibodies, derivatives and saccharide complexes/conjugates comprising heavy hydrogen isotopes. In some embodiments, the invention relates to racemizing amino acids starting from compositions of any optical purity. In further embodiments, the invention relates to the preparation of amino acids and their N-acyl counterparts with deuterium incorporated at the alpha carbon.
In accordance with an embodiment of the present invention, a method is provided for defining the portion of one or more chemical compounds having binding affinity for a target receptor. One or more chemical compounds to be tested are identified and then one or more key component fragments of the compound(s) are identified (e.g., a compound that “generically” defines the surface conformation and surface charge density of the one or more chemical compounds is “designed”) which may impart affinity for the target receptor. Analogs containing one or more of the key component fragments are then identified or synthesized, and the analogs are coupled to a carrier to construct an analog-carrier conjugate. The analogs contain one or more functional groups such as carboxyl, hydroxyl, keto, amino, nitro, or sulfhydryl to react with the carrier molecule. Next, the analog-carrier conjugate is utilized to generate a panel of monoclonal antibodies in vivo or in vitro, wherein the monoclonal antibodies are capable of defining the characteristics of the key component fragments. Next, the monoclonal antibodies are assayed to determine which are most specific for the key component fragments of the chemical compound(s) and which bind to the chemical compound(s). Competitive binding assays, or other assays are then preferably conducted to determine the ability of the monoclonal antibodies to discriminate between different chemical compounds.
Cancer-associated thrombosis (CAT) has been identified as the second most prevalent cause of death after cancer itself. Moreover, the risk of thrombotic events in cancer patients increases due to anticancer drugs, such as tyrosine kinase inhibitors (TKIs). Venous thromboembolism (VTE) as well as arterial thromboembolic (ATE) events are present in CAT. Although VTE occurs more frequently, ATE events are very significant and in some cases are more dangerous than VTE. Guidelines for preventing thrombosis refer mainly VTE as well as the contribution of ATE events. Several factors are involved in thrombosis related to cancer, but the whole pathomechanism of thrombosis is not clear and may differ between patients. The activation of the coagulation system and the interaction of cancer cells with other cells including platelets, endothelial cells, monocytes, and neutrophils are promoted by a hypercoagulable state caused by cancer. We present an update on the pathomechanisms of CAT and the effect of anticancer drugs, mainly targeted therapies with a focus on TKIs. Considering the risk of bleeding associated with anticoagulation in each cancer patient, the anticoagulation strategy may involve the use of FXIa inhibitors, direct oral anticoagulants, and low-molecular-weight heparin. Further research would be valuable in developing strategies for reducing CAT.
The invention features a computer-implemented method that stores a patient profile in electronic storage; the patient profile includes personal and medical information about the patient. The method provides access to a set of different health-related information tools. Each tool is a corresponding computer program which when executed uses information from the patient profile to generate corresponding health-related information about the patient and stores additional information about the patient in the patient profile. The additional information stored by each of the tools includes health-related information generated by that tool. The method also provides an interface enabling the patient to execute any selectable one of the health-related information tools among the set of different health-related information tools. The additional information stored in the patient profile by a first health-related information tool of the set is used by a second health-related information tool of the set during execution to generate its output.
This group includes 30 patients suffering from pain and loss of shoulder flexion ROM. Patients will recieve active-assisted ROM physical therapy 2 sessions per week for 4 weeks.
<P>PROBLEM TO BE SOLVED: To provide a nitrosoprotein capable of feeding NO into a living body by efficiently adding NO to a cysteine residue without changing a structure of a protein.  <P>SOLUTION: A stabilizer such as a fatty acid and/or an N-acetylamino acid is added to a protein. Thereby, a thiol group is reacted with NO to provide an S-nitrosoalbumin. Especially, when the protein is albumin, reactivity of 34th cysteine is increased and cysteine is rapidly reacted with NO by adding the stabilizer such as the fatty acid and/or the N-acetylamino acid to the albumin to provide the S-nitrosoalbumin. The S-nitosoprotein can enhance binding efficiency between SH group and nitrogen monoxide and stability thereof.  <P>COPYRIGHT: (C)2008,JPO&INPIT